Table 1 Population baseline characteristics
From: Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
| Characteristic (n = 28) | Mean ± SD or n (%) |
|---|---|
| Age (years) | 56.2 ± 13.4 |
| Females | 25 (89.3%) |
| BP | 14 (50%) |
| Smoker | 12 (42.86%) |
| Hypercholesterolemia | 10 (35.71%) |
| Diabetes Mellitus | 8 (28.57%) |
| History of ischemic cardiac disease | 2 (7.14%) |
| Left Breast Cancer | 18 (64.3%) |
| Radiotherapy | 9 (32.1%) |
| Ejection fraction (%) | 26.68 (5.35) |
| Creatinine (mg/dl) | 1.31 ± 0.16 |
| NYHA functional classification | |
| I | 0 (0%) |
| II | 0 (0%) |
| III | 22 (78.6%) |
| IV | 6 (21.4%) |
| Chemotherapy | |
| Doxorubicin | 23 (82.1%) |
| Cyclophosphamide | 23 (82.1%) |
| Docetaxel | 3 (10.7%) |
| Trastuzumab | 8 (28.6%) |
| Pertuzumab | 4 (14.3%) |
| Days since chemotherapy started | 183.6 ± 95.4 |
| Heart Failure treatment at enrollment | |
| Beta Blockers | 26 (92,85%) |
| ACEI | 12 (42.85%) |
| ARB | 13 (46.43%) |
| Digitalis | 9 (32.14%) |
| Mineralocorticoids antagonist | 18 (64.28%) |
| Diuretics | 20 (71.43%) |
| ICD | 3 (10.71%) |
| CRT-D | 2 (7.14%) |
| Heart transplant | 1 (3.6%) |